The sumatriptan difference.
Salonen
R
R
Neurology Clinical Development and Product Strategy, Glaxo Smith Kline, USA.
D000281:Administration, Intranasal; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008657:Metabolic Clearance Rate; D008881:Migraine Disorders / Q000188:drug therapy*; D018170:Sumatriptan / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D018170:Sumatriptan